Literature DB >> 26741817

Use of Noninvasive Parameters to Evaluate Swiss Webster Mice During Trypanosoma cruzi Experimental Acute Infection.

Jerônimo D S Campos1, Luanda Y Hoppe1, Thabata L A Duque1, Solange Lisboa de Castro1, Gabriel M Oliveira1.   

Abstract

Until now, there has been neither an agreed-upon experimental model nor descriptors of the clinical symptoms that occur over the course of acute murine infection. The aim of this work is to use noninvasive methods to evaluate clinical signs in Swiss Webster mice that were experimentally infected with the Y strain of Trypanosoma cruzi during acute phase (Inf group). Infected mice showed evident clinical changes beginning in the second week of infection (wpi) when compared to the noninfected group (NI): (1) animals in hunched postures, closed eyes, lowered ears, peeling skin, increased piloerection, prostration, and social isolation; (2) significant decrease in body weight (Inf: 26.2 ± 2.6 g vs. NI: 34.2 ± 2.5 g) and in chow (1.5 ± 0.3 vs. 6.3 ± 0.5 mg) and water (2.4 ± 0.5 vs. 5.8 ± 0.7 ml) intake; (3) significant decrease of spontaneous activity as locomotor parameters: distance (0.64 ± 0.06 vs. 1.8 ± 0.13 m), velocity (1.9 ± 0.3 vs. 6.7 ± 1.5 cm/sec), and exploratory behavior by frequency (1.0 ± 0.5 vs. 5.7 ± 1.0 events) and duration (1.4 ± 0.3 vs. 5.1 ± 0.5 sec in central arena region); (4) significant increase in the PR (41.7 ± 8.7 vs. 27.6 ± 1.9 msec) and QT intervals (39.7 ± 2.0 vs. 27.5 ± 4.0 msec), and a decreased cardiac frequency (505 ± 52.8 vs. 774 ± 17.8 msec), showing a marked sinus bradycardia and an atrioventricular block. At 3 and 4 wpi, the surviving animals showed a tendency of recovery in body weight, food intake, locomotor activity, and exploratory interest. Through the use of noninvasive parameters, we were able to monitor the severity of the infection in individuals prior to death. Our perspective is the application of noninvasive methods to describe clinical signs over the course of acute infection complementing the preclinical evaluation of new agents, alone or in combination with benznidazole.

Entities:  

Mesh:

Year:  2016        PMID: 26741817     DOI: 10.1645/15-884

Source DB:  PubMed          Journal:  J Parasitol        ISSN: 0022-3395            Impact factor:   1.276


  4 in total

1.  Rapamycin Treatment Reduces Acute Myocarditis Induced by Trypanosoma cruzi Infection.

Authors:  Thabata L A Duque; Cynthia M Cascabulho; Gabriel M Oliveira; Andrea Henriques-Pons; Rubem F S Menna-Barreto
Journal:  J Innate Immun       Date:  2019-12-04       Impact factor: 7.349

2.  Antiparasitic and anti-inflammatory activities of ß-lapachone-derived naphthoimidazoles in experimental acute Trypanosoma cruzi infection.

Authors:  Cynthia M Cascabulho; Marcelo Meuser-Batista; Kelly Cristina G de Moura; Maria do Carmo Pinto; Thabata Lopes Alberto Duque; Kelly C Demarque; Ana Carolina Ramos Guimarães; Pedro Paulo de Abreu Manso; Marcelo Pelajo-Machado; Gabriel M Oliveira; Solange L De Castro; Rubem Fs Menna-Barreto
Journal:  Mem Inst Oswaldo Cruz       Date:  2020-02-14       Impact factor: 2.747

3.  A New Antibiotic-Loaded Sol-Gel Can Prevent Bacterial Prosthetic Joint Infection: From in vitro Studies to an in vivo Model.

Authors:  John Jairo Aguilera-Correa; Amaya Garcia-Casas; Aranzazu Mediero; David Romera; Francisca Mulero; Irene Cuevas-López; Antonia Jiménez-Morales; Jaime Esteban
Journal:  Front Microbiol       Date:  2020-01-17       Impact factor: 5.640

4.  Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection.

Authors:  Juliana Magalhães Chaves Barbosa; Yasmin Pedra Rezende; Tatiana Galvão de Melo; Gabriel de Oliveira; Cynthia Machado Cascabulho; Evelyn Nunes Goulart da Silva Pereira; Anissa Daliry; Kelly Salomão Salem
Journal:  Microbiol Spectr       Date:  2022-02-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.